<DOC>
	<DOCNO>NCT02584959</DOCNO>
	<brief_summary>The purpose study assess efficacy safety subcutaneous administration liquid formulation C1 esterase inhibitor prevention angioedema attack adolescent adult subject hereditary angioedema .</brief_summary>
	<brief_title>Study Evaluate Clinical Efficacy Safety Subcutaneously Administered C1 Esterase Inhibitor Prevention Angioedema Attacks Adolescents Adults With Hereditary Angioedema</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>1 . Males female least 12 year age . 2 . Have diagnosis HAE ( Type I II ) functional C1 inhibitor ( C1 INH ) level le 50 % normal 3 . Averaging least 2 attack per month prior screen visit . 4 . If adult ( &gt; 18 year age ) , willing receive ondemand treatment icatibant treat angioedema attack study . 1 . Adults ( &gt; 18 yr age ) receive IV Cinryze prevention therapy exceed approve dosing 1000 U every 34 day ( receive weekly dose &gt; 2000U ) 2 . Adolescents ( &gt; 12 &lt; 18 year age ) currently receive C1 INH prevention therapy . 3 . If female , start change dose hormonal contraceptive regimen hormone replacement therapy within 2 month prior screen visit . 4 . Have history abnormal blood clot predisposition thromboembolism . 5 . Have diagnosis acquire angioedema know presence antiC1 INH antibody . 6 . Have history allergic reaction C1 INH product , include CINRYZE ( component CINRYZE ) , blood product .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>